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Insulin orchestrates physiological responses to ingested nutrients, however although it elicits 4 
widely ramifying metabolic and trophic responses from diverse tissues, "insulin resistance", a 5 
pandemic metabolic derangement commonly associated with obesity, is usually defined 6 
solely by blunting of insulin’s hypoglycaemic effect.  Recent study of monogenic forms of 7 
insulin resistance has established that biochemical subphenotypes of insulin resistance 8 
exist, clustering into those caused by primary disorders of adipose tissue, and those caused 9 
by primary defects in proximal insulin signalling.  Insulin resistance is often first recognised 10 
by virtue of its associated disorders, including type 2 diabetes, dyslipidaemia, fatty liver and 11 
polycystic ovary syndrome.  Although these clinically observed associations are confirmed 12 
by cross sectional and longitudinal population-based studies, causal relationships among 13 
these phenomena have been more difficult to establish.  Single gene insulin resistance is 14 
important to recognise in order to optimise clinical management, and also permits testing of 15 
causal relationships among components of the insulin resistance syndrome using the 16 
principle of Mendelian randomisation. Thus, where a precisely defined genetic defect is 17 
identified that directly produces one component of the syndrome, then phenomena that are 18 
causally linked to that component should be seen.  Where this is not the case, then a simple 19 
causal link is refuted. This article summarises known forms of monogenic severe insulin 20 
resistance and considers the lessons to be learned about the pathogenic mechanisms both 21 
upstream from common insulin resistance, and those downstream linking it to disorders such 22 




Origins of the concept of insulin resistance 1 
The discovery and clinical introduction of purified insulin in the early 1920s 2 
transformed diabetes mellitus from a rapidly fatal childhood malady into a 3 
manageable chronic disease.  However as the effort to translate therapeutic proof of 4 
principle into cheap, widely available insulin treatment gathered momentum in 5 
ensuing years, it became apparent that a subgroup of people with diabetes did not 6 
exhibit the dramatic response of the emaciated, ketotic patients first treated.  Most 7 
prominent in studying and articulating this was Harold Himsworth who, in the late 8 
1930s, discriminated between “sensitive diabetics” and “insensitive diabetics” 9 
(generally older, obese and hypertensive, commonly with arteriosclerosis, and 10 
exhibiting insidious disease onset with rare ketosis and insulin-induced 11 
hypoglycaemia)1.  Physiological studies showed that “insulin insensitive” patients 12 
were slow to show a hypoglycaemic response to exogenous insulin1.  Upon 13 
development of radioimmunoassays in 1960, formal proof was obtained that insulin 14 
resistant individuals do indeed have high or normal insulin levels in the face of 15 
hyperglycaemia2, 3.   16 
Now, nearly 100 years after the first use of insulin in diabetes, although the 17 
scourge of childhood death due to insulin deficiency is nearly vanquished, insulin 18 
resistance (IR) and the attendant hyperinsulinaemia sit at the centre of a web of 19 
burgeoning pandemic disease.  They are associated strongly with obesity4, type 2 20 
diabetes5, fatty liver disease6, "metabolic" dyslipidaemia4, polycystic ovary 21 
syndrome7, and some cancers8. However despite the clear documentation of these 22 
associations, understanding of the pathogenesis of IR, and whether and how it 23 
causes all the clinical conditions with which it is associated, remains incomplete. 24 
Mechanisms of insulin action 25 
Teasing out how insulin exerts metabolic and growth stimulating effects on 26 
target tissues has been the subject of painstaking biochemical study for many 27 
decades.  Around 40 years ago it was shown that insulin could bind competitively to 28 
hepatocyte membranes and thereby alter cellular metabolism9, and shortly 29 
afterwards the insulin receptor was identified biochemically10.  Sequencing of the 30 
gene for the human insulin receptor in 1985 demonstrated it to be a transmembrane 31 
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dimeric tyrosine kinase11, a member of what is now known as a large family of 1 
receptor tyrosine kinases of immense medical significance in endocrinology, cancer, 2 
and beyond.   3 
Cellular and animal studies have subsequently delineated many of the 4 
signalling events that pass the insulin signal from its receptor on the cell surface in 5 
order to change cellular metabolism and growth.  A detailed account of these, which 6 
have been comprehensively reviewed elsewhere12, 13, is beyond the scope of this 7 
article, however a simplified schematic is shown in Figure 1.  In brief, insulin binding 8 
to the receptor induces phosphorylation of its intracellular domains, leading to 9 
recruitment of several insulin receptor substrates, the most important of which are 10 
Insulin Receptor Substrates (IRS) 1 and 2.  These large phosphoproteins serve as a 11 
"platform" that initiates downstream signalling pathways, among which the 12 
phosphatidylinositol-3-kinase(PI3K)/AKT pathway and the MEK/ERK (formerly MAP 13 
Kinase) pathway have received most attention.  The PI3K pathway has traditionally 14 
been viewed as the key metabolic effector arm of the insulin signalling response, 15 
exerting critical metabolic actions in particular through AKT2, one of three isoforms 16 
of the serine-threonine kinase  AKT that is enriched in insulin-responsive tissues14.    17 
Several general features of the insulin signalling "pathway" bear particular note. 18 
First, although signalling downstream from the receptor is often conceptualised as a 19 
series of branching pathways emanating from the receptor or IRS proteins, there is 20 
both extensive crosstalk among branches of the signalling pathway and also 21 
negative feedback within them, so that they function as a rather more complex 22 
network than often implied by simple schematics.  Moreover, most of the signalling 23 
pathways downstream from the insulin receptor are shared by other receptor 24 
tyrosine kinases, and in particular the IGF1 receptor, whose signalling network is 25 
nearly indistinguishable from that of insulin.  How distinct biological responses are 26 
exerted by different growth factors and RTK ligands is not fully understood, though 27 
this is likely to depend in part on different patterns of ligand and receptor expression, 28 
and probably on different subcellular location of signalling molecules.  Second, it has 29 
previously been pointed out that at several key points of insulin signal transduction 30 
the signal may be transmitted by several different homologous proteins, some of 31 
which function as dimeric products of more than one gene12.  This introduces the 32 
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potential for huge combinatorial signalling complexity.  Finally, cellular studies are 1 
beginning to unpick the importance of different temporal sequences of signalling 2 
events after receptor stimulation, which, allied to different thresholds for activation of 3 
metabolic endpoints, introduces yet more tiers of signalling complexity15.   4 
All these considerations mean that, even at the refined level of cellular 5 
signalling, it is difficult to formulate one comprehensive, biologically meaningful 6 
definition of "insulin resistance", and doing so with reference to only one or even a 7 
handful of downstream readouts may mask a more complex and patchy perturbation 8 
of cellular signalling. As will be discussed, this may well be important for common 9 
diseases related to insulin resistance 10 
Quantitative Definitions of Insulin Resistance 11 
The catastrophic short term consequences of severe hypoglycaemia, and the 12 
damaging longer term consequences of hyperglycaemia, have meant that it is 13 
insulin's actions on blood glucose, rather than on other aspects of intermediary 14 
metabolism or growth, that have been by far the major focus of attention over the 15 
past century16.  Thus it is by reference to insulin's ability to lower blood glucose that 16 
insulin sensitivity, and thus resistance, is generally defined17.  The simplest 17 
definitions rely on measurement of fasting plasma insulin together with blood 18 
glucose.  When blood glucose is in the normal range, IR may simply be defined 19 
using an arbitrary threshold established with reference to fasting insulin in a 20 
reference population.  Where beta cell decompensation and hence hyperglycaemia 21 
have arisen, use of an empirical index such as the HOMA-IR index is of use.  More 22 
complicated dynamic testing may also be used, including oral or intravenous glucose 23 
tolerance testing with derivation of one of a variety of indices, while determination of 24 
the amount of insulin required in the face of a fixed infusion of glucose to maintain 25 
normal blood glucose (so-called hyperinsulinaemic euglycaemic clamping) is 26 
generally held to be the gold standard.  However although each of these approaches 27 
has utility, and while several permit assessment of different aspects of insulin's 28 
glucose lowering action, each neglects the effect of insulin on other processes such 29 
as amino acid and lipid metabolism.  Although efforts have been made to develop 30 
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surrogate indices of IR based on other plasma analytes18, 19, none of these has yet 1 
been widely clinically adopted. 2 
As insulin sensitivity is a continuous trait, thresholds for diagnosis of “severe” IR 3 
are arbitrary, and ideally should be defined with reference to appropriate controls, 4 
taking into account such influences on insulin sensitivity as age, sex, pubertal stage, 5 
obesity and concomitant medical illness.  Operational examples of thresholds for 6 
defining severe IR are a requirement for exogenous insulin of greater than 3 7 
units/kg/day to maintain normoglycaemia in those with absolute insulin deficiency, or 8 
a fasting insulin greater than 150 pmol/l in lean adults without diabetes.  However 9 
given the complexity of setting valid numerical thresholds, especially once diabetes 10 
has developed, clinical evidence of severe IR from history and examination are of 11 
tremendous importance in timely diagnosis.   12 
Mendelian Randomisation to Test Causality in Human Disease 13 
A key challenge in studies of IR-associated disease in humans arises from the 14 
difficulty in discerning cause and effect, if any, in observed associations.  Causality 15 
may be implied though not proven from the sequence of appearance of clinical 16 
phenomena, however the most direct test of whether a disease is caused by an 17 
associated disorder in humans is to directly introduce that perturbation, and to 18 
observe whether the disease ensues.  In most cases, however, even where this 19 
might technically be possible, the postulated deleterious nature of the first 20 
perturbation, and/or the time course over which the disease of interest develops 21 
render this impractical or unethical.  Natural genetic variation may sometimes be 22 
used opportunistically to undertake equivalent studies, where a primary genetic 23 
cause of a candidate mediator of disease can be identified.  An often cited paradigm 24 
for this so-called "Mendelian randomisation" approach lies in Brown's and 25 
Goldstein's use of patients with LDL receptor mutations and thus primary elevation of 26 
LDL cholesterol to provide strong evidence for the causal link between high LDL 27 
cholesterol and atherosclerosis20.  The principle of Mendelian randomisation is 28 
illustrated in Figure 2. 29 
Mendelian randomisation would also be of value in principle in testing which of 30 
the IR-associated diseases are indeed caused by IR, as long as primary genetic 31 
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causes of IR, with no independent link to the diseases being studied, could be 1 
identified.  Such groups of patients with primary monogenic IR are indeed now 2 
known, and continue to be discovered, and their value in informing studies of 3 
common IR-related disease will be the main focus of the rest of this article. 4 
An Analytic "Toolkit": Subtypes of Human Monogenic Insulin Resistance 5 
It is 27 years since the first single gene form of severe IR, caused by mutations 6 
in the gene encoding the insulin receptor, was discovered21, 22, and in the past 17 7 
years further disorders have been added to this, latterly with increasing rapidity as 8 
modern genetic technologies have been brought to bear23.  As the number of known 9 
monogenic disorders has increased, so it has become apparent that IR is not 10 
monomorphic, and indeed that most single gene causes of severe IR do not directly 11 
affect insulin cellular signalling pathways. Instead, many defects do directly affect the 12 
development or function of adipose tissue, with secondary effects on insulin action in 13 
vivo.  Single gene causes of severe IR may thus be divided into groups loosely 14 
defined by the tissue or cellular process affected.  It is these groupings which are 15 
lending increasing power to Mendelian randomisation. 16 
Primary insulin signalling defects: The first human loss-of-function mutations 17 
were reported in the insulin receptor in 1988, both in Donohue Syndrome, an 18 
extreme infantile form of failure to thrive with IR22 or with the less severe “type A” 19 
form of IR21, which usually becomes manifest peripubertally.  Since this time more 20 
than a 150 different mutations within the insulin receptor have been discovered, with 21 
relatively few recurring mutations, and the phenotypic spectrum has been well 22 
described elsewhere23-25.  A single family with four members affected by severe IR 23 
due to a loss-of-function mutation in AKT2 was also described in 2004, and was the 24 
second example of a highly penetrant  Mendelian form of severe IR due to mutation 25 
of a canonical insulin signalling gene26.  Mutations in TBC1D4, involved in regulating 26 
exocytosis of glucose-transporting GLUT4 vesicles in response to insulin, were 27 
described also described in association with an apparently muscle-selective form of 28 
severe IR27, and this was later confirmed in a Greenland population, where a similar 29 
genetic defect accounts for a significant part of the variance of insulin sensitivity28.   30 
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The latest form of severe IR established to be caused by mutation of an insulin 1 
signalling gene is seen in the context of SHORT syndrome, denoted by Short 2 
Stature, joint Hyperextensibility and Hernias, Ocular depression, and Teething delay.  3 
Although not part of the acronym, severe IR has been shown to be common in this 4 
disorder, and in 2012 the underlying cause was established to be mutations in the 5 
PIK3R1 gene29-31. PIK3R1 encodes three of the regulatory subunits of type 1A 6 
phosphatidylinositol-3-kinase, which are critical for the coupling of insulin binding to 7 
its receptor to activation of AKT2 and other downstream signalling molecules12.  8 
Primary insulin signalling disorders are schematised in Figure 1. 9 
Primary Lipodystrophies 10 
Inherited disorders of adipose tissue development, or lipodystrophies, were 11 
described clinically from at least the 1920s32, however it has only been in this century 12 
that they have yielded to genetic study, with many different causal genetic defects 13 
now identified.  Inherited lipodystrophies are most commonly divided into those that 14 
feature complete, or near complete absence of all adipose tissue, called congenital 15 
generalised lipodystrophy (CGL), and those in which only some adipose tissue 16 
depots are affected, called familial partial lipodystrophy.  17 
CGL, often known as Berardinelli–Seip congenital lipodystrophy, is caused in 18 
around 95% of cases by biallelic mutations in one of two genes, namely AGPAT2, 19 
encoding 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2)33, 34, and 20 
BSCL2, which encodes a transmembrane endoplasmic reticulum protein named 21 
seipin35.  Seipin plays a role in preadipocyte differentiation36 and in the regulation of 22 
lipid droplet synthesis and function37, 38.  Smaller numbers of patients with CGL have 23 
also been reported with loss-of-function mutations in CAV139 or PTRF40, the latter 24 
associated also with myopathy.  Both these genes encode key structural 25 
components of small plasma membrane invaginations called caveolae, which 26 
account for up to 40% of the adipocyte surface area, and play an important role in 27 
organising cell signalling and lipid trafficking.  Most recently, genetic disruption of 28 
PCYT1A, encoding phosphate cytidylyltransferase 1, which plays a key role in de 29 




Familial partial lipodystrophies (FPLD) are collectively far more common than 1 
CGL.  They are usually not clinically manifest until puberty, when perturbation of 2 
pubertal adipose accretion unmasks the underlying abnormality.  Women are more 3 
severely affected than men, likely due in large part to the naturally greater adiposity 4 
of women than men.  At least seven genes with diverse roles in adipocyte biology 5 
have now been linked to partial lipodystrophy (Table 1).  The first of these, LMNA, 6 
encodes a nearly ubiquitously expressed intermediate filament protein, Lamin A/C, 7 
which forms part of a structural network of proteins supporting the nuclear 8 
membrane42. Different LMNA mutations have also been linked to other disorders 9 
including muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth 10 
neuropathy, premature aging syndromes, restrictive dermopathy and various overlap 11 
syndromes43. The mechanism(s) linking LMNA mutations to lipodystrophy are not 12 
fully understood, but roles have been proposed for structural defects in the nuclear 13 
envelope, and/or abnormal binding of the nuclear lamina to chromatin and 14 
transcription factors, thus altering gene expression.  15 
The second gene to be affected in familial partial lipodystrophy is PPARG44, 16 
encoding PPAR, a nuclear hormone receptor most highly expressed in adipose 17 
tissue where it is essential for adipocyte differentiation, and which is the target of the 18 
thiazolidinedione class of antidiabetic agents. All known pathogenic mutations are 19 
heterozygous, and most have been shown to inhibit the function of co-expressed 20 
wildtype protein.  21 
Although the remaining genes now known to cause partial lipodystrophy 22 
collectively account for only a tiny proportion of cases, their discovery has 23 
highlighted the critical importance of lipid droplet dynamics in human metabolic 24 
homeostasis, with defects in either CIDEC45 or Perilipin46, each of which resides on 25 
the surface of the lipid droplet and plays a regulatory role in triglyceride mobilisation, 26 
now implicated in human partial lipodystrophy. 27 
Of note, several of the primary insulin signalling disorders also feature some 28 
degree of lipodystrophy, in keeping with an important role for insulin and IGF1 29 
signalling in adipocyte differentiation.  This is particularly pronounced in the case of 30 
AKT2 loss of function26 and in SHORT syndrome29, 31, but a generalised paucity of 31 
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adipose tissue is also commonly described in the more severe insulin 1 
receptoropathies.  The potential importance of this for the IR subphenotype that is 2 
clinically expressed is discussed below. 3 
Complex Monogenic Disorders Featuring Severe Insulin Resistance 4 
A clinically heterogenous group of more complex monogenic conditions also 5 
exists that features severe IR disproportionate to whole body adiposity. These 6 
include the premature ageing syndromes Werner Syndrome47, 48 and Bloom 7 
Syndrome49, both caused by defects in DNA helicases, and a very recently 8 
described syndrome of primordial dwarfism caused my mutations in the NSMCE2 9 
gene, which encodes a component of the Structural Maintenance of Chromosomes 10 
(SMC) 5/6 complex50.  Each of these genes plays some role in permitting dividing 11 
cells to tolerate DNA damage, and in the maintenance of telomeres.  Another 12 
recently described syndrome featuring loss of subcutaneous fat as well as severe IR 13 
is caused by heterozygous loss-of-function mutations in POLD1, encoding DNA 14 
polymerase delta, the dominant lagging strand DNA synthase in human cells51.  This 15 
adds to the impression that some aspects of DNA damage repair or replication are 16 
critical to metabolic homeostasis.  This notion is lent further credence by the 17 
observation that childhood irradiation as part of cancer therapy predisposes to later 18 
dyslipidaemia and IR, which may sometimes be severe52.  Modelling of this 19 
phenomenon in leptin deficient, severely obese mice suggests that irradiation leads 20 
to adipocyte and preadipocyte death, effectively reducing adipose tissue 21 
expandability, leading to a worsened metabolic state because if, rather than despite, 22 
a reduction in adipose gain after irradiation53. 23 
A further tantalising hint of a specific relationship between a particular cellular 24 
function and whole body metabolic IR comes from the observation of severe IR in 25 
patients with genetic defects in different centrosomal components including ALMS1 26 
54, PCNT 55, 56, and POC1A57. Teasing out the pathogenic link between the defined 27 
molecular defect and severe systemic IR in these disorders promises to yield novel 28 
insights in future into the mechanistic basis of IR.  Given the complex and pleiotropic 29 
nature of the genetic defects, however, these conditions are not suitable as a basis 30 
for the Mendelian randomisation approach. 31 
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Application of Mendelian Randomisation to Obesity-Associated Metabolic 1 
Disease 2 
Many of the disorders described above, where the cellular function and 3 
immediate physiological consequences of the genetic defect can be defined with 4 
confidence, are appropriate instruments to use in a Mendelian randomisation-based 5 
attempt to address important questions about the causes and consequences of 6 
human IR. Several of these questions will be considered in turn, and the lessons to 7 
be drawn from monogenic disease will be assessed. 8 
How does Obesity Give Rise to Insulin Resistance? 9 
Cross sectional and longitudinal studies suggest strongly that obesity is the 10 
proximate cause of most pandemic IR, however the question then arises of the 11 
mechanistic link between these phenomena.  Study of humans with single gene 12 
defects producing severe, early onset, hyperphagic obesity, for example due to 13 
genetic deficiency of either leptin or its receptor, confirm that IR is common in this 14 
group, however it is often not severe, and its severity is often somewhat less than 15 
that of the concomitant obesity. This implies that there are factors other than severity 16 
of obesity which influence the degree of obesity-related IR.  Importantly, at the 17 
opposite end of the adipose spectrum, patients with congenital generalised 18 
lipodystrophy, who have negligible adipose tissue, develop extremely severe IR, 19 
dyslipidaemia and fatty liver, and thus monogenic lipodystrophy has been argued to 20 
be a potentially aetiologically informative model of the common metabolic 21 
syndrome58. 22 
These human observations lend strong support to the hypothesis that it is 23 
relative adipose failure that is critical to the pathogenesis of the obesity-related 24 
metabolic syndrome rather than the degree of obesity.   According to this idea, the 25 
capacity of adipose tissue to continue expanding, while safely storing excess 26 
calories in the form of triglyceride, is finite, and when this capacity, which shows 27 
considerable inter-individual variation is exceeded, then "adipose failure", with 28 
knock-on effects on other, insulin-sensitive tissues, ensues59-61.  Congenital 29 
generalised lipodystrophy represents an extreme example of this, where the adipose 30 
energy buffering capacity is negligable.  In this setting patients remain lean, however 31 
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loss of the capacity of adipose tissue to buffer excess caloric intake by serving as a 1 
sump for free fatty acids and, to a much lesser extent, as a site of disposal of 2 
glucose is likely to result in remodelling of systemic free fatty acid flux, with 3 
increased uptake in other metabolically critically tissues such as liver, skeletal 4 
muscle and pancreatic beta cells, where harmful effects including loss of insulin 5 
sensitivity, secretory dysfunction and apoptosis may result62.  This series of 6 
maladaptive changes are collectively unified by the term lipotoxicity. 7 
In many monogenic partial lipodystrophies significant adipose depots remain, 8 
and indeed it is not uncommon for whole body adiposity to be elevated, as assessed 9 
by direct measurement and by surrogate indices such as plasma leptin levels. In 10 
these conditions it is adipose topography which appears to be critical to metabolic 11 
homeostasis.  In all known genetic forms of partial lipodystrophy which feature 12 
severe IR femorogluteal depots are affected, while central fat and omental fat are 13 
often preserved or increased, meaning that Cushing’s syndrome is commonly 14 
invoked as a differential diagnosis at first assessment.  The impression that lower 15 
body subcutaneous fat is critical for metabolic health is bolstered by the observation 16 
that in acquired partial lipodystrophy, where subcutaneous fat is usually lost in a 17 
craniocaudal direction to the level of the umbilicus, there is only a low rate of 18 
systemic metabolic derangement63.  Distributions of fat loss in partial lipodystrophies 19 
are illustrated in Figure 3. 20 
Importantly, although  some of the genes involved in lipodystrophy are 21 
expressed in cells other than adipocytes, raising concerns that they may exert 22 
phenotypic effects unrelated to lipodystrophy, thus invalidating them as instruments 23 
for Mendelian randomisation-based analysis, the closely similar metabolic phenotype 24 
seen in patients with acquired, autoimmune, lipodystrophy, and the fact that a least 25 
one of the genes implicated in genetic lipodystrophy, PLIN, is adipocyte-specific46, 26 
argues against this. 27 
Additional mechanisms beyond loss of energy buffering have been invoked to 28 
account for the link between increased adipose tissue and IR.  One of these is 29 
perturbation of circulating levels of adipose-derived hormones, the so called 30 
adipokines.  Evidence for a large number of these has now been put forward, but in 31 
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most cases evidence for a critical role in setting systemic insulin sensitivity is mixed, 1 
and most are best viewed as playing an accessory role only. Apart from leptin, best 2 
established of the bona fide adipokines, adiponectin, a large protein with homology 3 
to complement factor C1q, has attracted the most sustained and intense attention.  It 4 
circulates at high levels in plasma as a complex mixture of oligomeric or multimeric 5 
forms.  Unusually, increasing levels of adiposity and IR are associated with lower 6 
plasma adiponectin concentration, with a concomitant shift from higher molecular 7 
weight species to lower molecular weight forms.  Much of the evidence that 8 
adiponectin is an insulin sensitiser come from murine studies.  Genetic ablation of 9 
the adiponectin-encoding gene in mice produced IR in some, though not all reports, 10 
while administration of various different oligomeric adiponectin preparations has 11 
been shown in mice to improve insulin sensitivity64, 65.   12 
The metabolic role of adiponectin in humans is less clear.  Until recently 13 
evidence for a causal role of low adiponectin in IR was largely correlative, based on 14 
studies of association of plasma adiponectin with metabolic disorders64. However 15 
genetic studies, several involving Mendelian randomisation, have also now been 16 
brought to bear on this issue.  Plasma adiponectin is usually either preserved or 17 
frankly elevated, sometimes dramatically so, in the face of either genetic or acquired 18 
defects in insulin receptor function66-68, and more limited evidence suggests that this 19 
is also true in SHORT syndrome, arguing that proximal defects in insulin signalling 20 
raise plasma adiponectin.  This observation is not explained, but demonstrates that 21 
suppressed plasma adiponectin is not a consequences of reduced insulin signalling.  22 
Indeed, it may be viewed as an attempt to ameliorate insulin sensitivity in the face of 23 
a fixed signalling defect.  A more direct test of adiponectin’s potential to influence 24 
insulin sensitivity comes from true Mendelian randomisation, whereby association 25 
with IR of genetic variants at the locus of the adiponectin gene, ADIPOQ, that induce 26 
primary changes in plasma adiponectin, are assessed.  This approach has been 27 
adopted by several groups with mixed results.  Two studies found that genetically-28 
determined lowering of plasma adiponectin did indeed associate with reduced insulin 29 
sensitivity69, 70, while the largest study, with the greatest statistical power, found no 30 
such association71.  One family has been reported in which a rare missense ADIPOQ 31 
variant suppressing plasma adiponectin was found to associate with IR72.  More 32 
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systematic metabolic study of more families with rare ADIPOQ alleles identified in 1 
large scale exome sequencing studies will be of value to identify any that suppress 2 
plasma adiponectin, and to clarify the association further. 3 
Does Insulin Resistance Cause Fatty Liver and Dyslipidaemia? 4 
Understanding the relationship between plasma adiponectin levels and IR is 5 
important for the understanding of the pathogenesis of IR, and this is given extra 6 
weight by the potential exploitation of adiponectin for therapeutic benefit.  7 
Nevertheless low plasma adiponectin is a biochemical surrogate rather than a 8 
clinical disease.  In contrast, the fatty liver disease spectrum, which is intimately 9 
linked to a pattern of dyslipidaemia characterised by low plasma HDL cholesterol 10 
and high plasma triglyceride, exacts an immense toll of human suffering.  To this, 11 
too, Mendelian randomisation using rare disorders of insulin action may be applied.  12 
Before diabetes supervenes, primary IR due to genetic defects in the insulin receptor 13 
is a model of global, compensated IR with extreme hyperinsulinaemia.  Strikingly, 14 
however, patients with genetic or acquired INSR defects appear to be entirely 15 
protected from "metabolic" dyslipidaemia73.  Moreover, they do not exhibit increased 16 
liver fat, and rates of hepatic de novo lipogenesis, which has been proposed to be an 17 
important contributor to fatty liver and dyslipidaemia in human IR74, 75, are similar to 18 
controls73.  This argues that fatty liver disease and dyslipidaemia can be accounted 19 
for neither by generalised IR, nor by severe hyperinsulinaemia acting through non 20 
insulin receptor-dependent pathways. 21 
Analysis of IR due to downstream signalling defects produces contrasting 22 
results: preliminary data suggests that in SHORT syndrome due to mutations in 23 
PIK3R1, lipid profiles are normal despite severe IR31, while in contrast, 2 patients 24 
studied with severe IR due to defects in AKT2, three steps down the classical insulin 25 
signalling pathway from the insulin receptor and one from PI3K, did show 26 
exaggerated metabolic dyslipidaemia with severe fatty liver73.   27 
These human observations suggest that “partial” IR – that is, IR affecting only 28 
some parts of the insulin signalling network, may play an important role in the 29 
pathogenesis of major IR-related pathologies.  This hypothesis was first widely 30 
promulgated in the 1980s4, and has been supported previously by observations 31 
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made in genetically modified mice76.  In the current context, “partial” IR may either be 1 
regarded as a cell autonomous phenomenon, whereby the pathway required for 2 
hyperinsulinaemia to drive liver fat accumulation and atherogenic patterns of VLDL 3 
secretion from liver cells depends on the insulin receptor and PIK3R1 but not AKT2, 4 
implying a signalling pathway proximal to AKT2 that drives hepatic de novo 5 
lipogenesis. However this is at odds with most of the considerable body of murine 6 
data, most of which suggest that AKT2 is critical in mediating the effect of insulin to 7 
drive liver fat accumulation77, 78.  Other possibilities are that the critical elements of 8 
“partial” IR are differential effects of the same fixed defect in insulin signalling on 9 
different downstream pathways due to differing thresholds for activation79 and/or 10 
differential effects of the same fixed defect on insulin sensitivity of different tissues80.  11 
Thus, it may be that the dominant effect in humans of the AKT2 mutation reported is 12 
in adipose tissue, where AKT2 is involved in suppressing adipocyte differentiation 13 
and the suppression of lipolysis, and that the resulting “adipose failure” swamps 14 
reduced ability of high insulin to drive de novo lipogenesis in the liver  Possible 15 
models of partial IR are schematised in Figure 4. 16 
Does Insulin Resistance Cause Polycystic Ovary Syndrome? 17 
Like type 2 diabetes, polycystic ovary syndrome has a high prevalence, 18 
estimated to be of the order of 10% in Western populations, and confers a high 19 
burden of morbidity, due in particular to subfertility and to  psychological distress 20 
related to the cosmetic effects of clinical hyperandrogenism.  However like the label 21 
"type 2 diabetes", the label "PCOS" does not imply aetiopathogenesis. Instead it 22 
simply describes the syndrome, and is the unifying designation for the common 23 
clinical expression of a range of primary underlying defects rather than being a single 24 
entity.  Indeed, although PCOS has been the focus of an extensive literature 25 
encompassing clinical, model organism and cellular studies, debate continues about 26 
key aspects of its pathogenesis.  27 
IR and the metabolic syndrome are very well described associations of PCOS, 28 
with a prevalence in the region of 50-70%, depending on definitions used and 29 
population studied81, 82.  However there has been uncertainty as to whether IR in 30 
PCOS has unique characteristics.  Moreover primary androgen excess of a variety of 31 
16 
 
causes may reduce insulin sensitivity in adipose and other tissues, so an argument 1 
has sometimes been made that the IR in PCOS is caused by ovarian dysfunction 2 
rather than vice versa.  Where IR is accepted as a cause of some forms of PCOS, 3 
partial IR, as in the liver, has been invoked to explain PCOS, with the ovary argued 4 
to be an non insulin-resistant “bystander” tissue, responding to high levels of 5 
circulating insulin set by selective defects in the metabolic actions of insulin in other 6 
tissues83. 7 
In the face of complex and sometimes competing hypotheses, observations in 8 
humans with single gene severe IR are simple:  Ovulatory dysfunction and 9 
hyperandrogenism, which may be very severe, are seen in nearly all known 10 
monogenic forms of severe IR.  They are seen in exaggerated form in the context of 11 
genetic or acquired insulin receptoropathy, of downstream insulin signalling defects 12 
in AKT2 or PIK3R1, of partial or generalised lipodystrophy and pleiotropic 13 
syndromes, all of which commonly exhibit severe clinical and biochemical 14 
hyperandrogenism, oligo- or amenorrhoea and classical polycystic ovaries.  In other 15 
words, while dyslipidaemia and fatty liver are seen only in some types of IR, the 16 
ovarian phenotype is nearly universal. There is no evidence that it differs between 17 
global IR at the level of the receptor, and selective IR affecting PI3K/AKT signalling, 18 
generally regarded as the more metabolic arm of the insulin signalling pathway, in 19 
keeping with prior evidence that PI3K does not mediate the effects of insulin on 20 
human granulosa cells in culture84.  Furthermore, although perturbed androgen 21 
metabolism has been suggested to play an important role in PCOS in some forms of 22 
insulin resistance85, the severe PCOS seen in generalised lipodystrophy argues that 23 
adipose androgen is not an obligate link between severe IR and PCOS. 24 
In Donohue syndrome cystic ovarian enlargement may be seen in infancy, and 25 
this can be massive, even when no functional insulin receptors are expressed86, 87.  26 
While this ovarian pathology is not identical to that of polycystic ovary syndrome, it is 27 
plausible to suggest that it shares the same underlying mechanism, namely synergic 28 
stimulation of follicles by extremely elevated insulin and the gonadotrophins which 29 
are elevated in the early months of life before secondary suppression. If this parallel 30 
holds true, then this suggests that the adverse effects of insulin on the ovary need 31 
not be exerted through the insulin receptor itself.  These observations suggest that 32 
17 
 
the ovarian component of the IR syndrome, quite unlike fatty liver and dyslipidaemia, 1 
do not require intact INSR function, although they do require severe 2 
hyperinsulinaemia.  These findings may be reconciled by hypothesizing that very 3 
high levels of insulin enhance signalling through the IGF receptor, in keeping with a 4 
large body of evidence for an important role for IGFs in follicular maturation88, 89. 5 
PCOS is reported to be common in premenopausal women with acromegaly90, 6 
however it is not usually as severe as that seen in the context of severe IR.  This 7 
discrepancy may be accounted for by endocrine or paracrine enhancement of IGF1 8 
bioavailability or receptor expression in IR in addition to an IGF-like action of very 9 
high levels of circulating insulin. 10 
Observations in defined monogenic forms of severe insulin resistance may not 11 
necessarily be extrapolatable to “common” PCOS.  On the other hand, the extremely 12 
high penetrance of a PCOS phenotype in the face of a diverse array of genetic forms 13 
of severe IR, and the reversible PCOS seen in acquired states of insulin receptor 14 
dysfunction91, which are not mimicked by insulin deficient states, show that IR with 15 
compensatory hyperinsulinaemia is sufficient to cause a severe PCOS-like state 16 
without needing to invoke additional mechanisms or the importance of a specific 17 
subtype of insulin resistance.  The ability of primary hyperandrogenaemia due to 18 
genetic abnormalities in steroid metabolism also to phenocopy prevalent PCOS92 19 
reaffirm, however, that there is more than one pathway to the PCOS phenotype. 20 
Does Insulin Resistance Cause Cancer? 21 
Increasing attention has been paid in recent years to the association in 22 
population-based studies between IR and some cancers, including those of the 23 
breast, colon, prostate and endometrium93.  For some cancers there are plausible 24 
endocrine or metabolic explanations for a causal link between IR and the tumour that 25 
do not involve direct effects of insulin on the tumour itself. For example, 26 
hyperinsulinemia induces the oestrogen replete but oligomenorrhoeic state 27 
commonly seen in PCOS, indirectly increasing risk of endometrial cancer94.  28 
Furthermore it is well established that the fatty liver associated with lipodystrophy is 29 
not benign, but rather features a high risk of cirrhosis and ultimately hepatocellular 30 
18 
 
cancer in lipodystrophies95.  However it has also been argued, with some 1 
experimental evidence, that insulin may directly drive tumour growth93, 96. 2 
Cancer pathogenesis is complex and multifactorial, and hyperinsulinaemia is 3 
likely to be only one facilitatory element in a complex sequence of events.  4 
Nevertheless it is to be predicted that in severe monogenic forms of IR the cancer 5 
risk may be further increased from the risk attributed to IR in the general population.  6 
Indeed, several non malignant elements of the severe IR syndrome, namely the 7 
dermal and epidermal hyperplasia of acanthosis nigricans, the organomegaly of 8 
infantile receptoropathy, and the pseudoacromegaloid soft tissue overgrowth 9 
common to many forms of IR, attest to the tissue defective growth-promoting effects 10 
of hyperinsulinaemia.  In the most severe hyperinsulinaemia seen in Donohue 11 
syndrome, ovarian tumours may arise in infancy86, 87, while colonic polyposis is also 12 
sometimes seen in either recessive or dominant insulin receptoropathies.  Thus, 13 
while syndromes of severe insulin resistance, except those featuring an underlying 14 
defect in DNA damage repair such as Werner and Bloom’s syndromes, are not 15 
penetrant cancer predisposition syndromes, the mitogenic consequences of 16 
sustained severe hyperinsulinaemia are apparent, and this adds weight to the notion 17 
of a role for hyperinsulinaemia per se in increasing prevalent cancer risk. 18 
Conclusions and Future Directions 19 
IR is not a disease in itself, but rather an endocrine derangement associated 20 
with several pandemic diseases and tissue pathologies.  Study of rare single gene 21 
forms of insulin resistance has yielded valuable insights into several aspects of the 22 
pathogenesis of these diseases.  Current findings are consistent with the “adipose 23 
failure” model linking obesity to prevalent metabolic disease, and suggest that 24 
compensatory hyperinsulinaemia may play a critical role in the pathogenesis of 25 
PCOS as well as fatty liver and metabolic dyslipidaemia.  Specifically, differences 26 
among different subtypes of insulin signalling defect demonstrate that insulin 27 
resistance with respect to glucose lowering may be uncoupled from other 28 
components of the prevalent metabolic syndrome including fatty liver and 29 
dyslipidaemia, depending on the precise nature of the underlying signalling defect.  30 
In contrast the “trophic” features of insulin resistance including acanthosis nigricans, 31 
19 
 
soft tissue overgrowth and PCOS are seen in essentially all insulin resistant 1 
hyperinsulinaemic states.  Teasing out the mechanistic basis of these findings in 2 
humans offers the possibility to identify novel strategies to isolate and treat several 3 
different components of the complex of obesity and insulin resistance-related 4 
diseases.  5 
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Table 1: Known genetic forms of partial lipodystrophy 3 
Clinical 
Disorder 
Gene Inheritance Distribution of 
Adipose Loss 
Comment 
FPLD2 LMNA AD S/C sparing head, 
neck and labia 
majora 
Commonest cause of FPLD.  May be 
mistaken for Cushing’s syndrome 
due to preserved head and neck fat 
FPLD3 PPARG AD Limbs LD may be subtle, limited to limbs, 
and associated with centripetal 
obesity 
FPLD4 PLIN1 AD Limbs  
FPLD6 AKT2 AD Limbs Single family reported to date 
FPLD5 CIDEC AR Limbs Single patient reported 
SHORT 
Syndrome 
PIK3R1 AD or 
sporadic 




POLD1 AD or 
sporadic 
S/C Also loss of limb muscle, 
scleroderma-like features, deafness 
and male hypogonadism 
FPLD = Familial Partial Lipodystrophy; SHORT = Short stature, Hyperextensibility, Ocular depression, 4 
Hernias, Rieger Anomaly; MDP = Mandibular hypoplasia, Deafness, Progeroid features; AD = autosomal 5 






Figure 1: Simplified Schematic of Insulin Signalling Pathway with Known 3 
Human Monogenic Disorders.  Genes that have been implicated in Mendelian 4 
disorders of insulin signalling are shown in red with the corresponding disease and 5 
year of discovery in linked boxes.  Cellular process stimulated by insulin are shown 6 
in green, while those inhibited by insulin are shown in red italics.  INS = insulin; INSR 7 
= the insulin receptor; IRS1/2 = Insulin receptor substrate 1/2; Phosphatidylinositol-3-8 
Kinase is illustrated as a heterodimer of of one of two catalytic subunits (p110 or 9 
p110) and one of four regulatory subunits, three of which (p85, p55, p50) are 10 
encoded by the PIK3R1 gene mutated in SHORT syndrome.  PIP2 = 11 
Phosphatidylinositol-(4,5)-bisphosphate; PIP3 = Phosphatidylinositol-(3,4,5)-12 
trisphosphate; PDK1 = 3-phosphoinositide dependent protein kinase-1; AKT = 13 
Protein kinase B; GSK3 = Glycogen synthase kinase 3; FOXO1 = Forkhead box 14 
protein O1 (FOXO1); mTORC1/2 = Mammalian target of rapamycin complex 1/2; 15 
TBC1D4 =  gene encoding AKT substrate of 160KDa; BAD = ;PDE3B = ;SREBP1c = 16 
; SHC = Src-homology-2-containing protein; GRB2 = Growth factor receptor-bound 17 
protein 2; SOS = Son of Sevenless; MEK = MAPK/ERK Kinase ;ERK = Extracellular 18 
signal-regulated kinases. 19 
 20 
Figure 2: Principle of Mendelian Randomisation. Algorithm for the use of 21 
Mendelian disorders to test possible causality underlying biological association, 22 




Figure 3: Distribution of Adipose Loss in Lipodystrophies.  Areas of deficient 1 
adipose tissue are illusrtaed in red, with preserved adipose tissue represented in 2 
green.  CGL = congenital generalised lipodytrophy; FPLD = familial partial 3 
lipodystrophy; APLD = acquired partial lipodystrophy; WAT = white adipose tissue; 4 
s/c = subcutaneous; BM = bone marrow; IR = insulin resisance; DL = dyslipidaemia; 5 
NAFLD = non alcoholic fatty liver disease.  6 
 7 
Figure 4: Models for Role of Partial Insulin Resistance in Disease 8 
Pathogenesis.  Hypoglycaemic and lipogenic actions of insulin are used to illustrate 9 
each model.  A.  Cell autonomous selective signalling defect model, with  10 
disproportionate attenuation of insulin action to lower glucose, leading to 11 
compensatory hyperinsulinaemia, and exposure of intact insulin signalling pathway, 12 
to higher levels of insulin action.  B. Differential dose response model.  This is a 13 
variation of the above theme whereby a fixed reduction in insulin action across all 14 
arms of the signalling pathway has a greater effect on arms of the pathway showing 15 
a shallow dose response curve to insulin than those showing a steep dose response 16 
curve.  C. Differential tissue resistance to insulin model.  Where an organ with the 17 
dominant role in insulin-mediated glucose disposal is more insulin resistant than 18 
other tissues, it effectively sets the level of systemic insulin, potentially exposing 19 
other more responsive tissues to abnormally high insulin action.  These models are 20 
non mutually exclusive and may all play some role in vivo. 21 


































































A                          B
Observed 
Association
Does A cause B?
Can A be safely induced in 
humans for long enough to 
observe incidence of B?
Do genetic variants exist which 
directly cause A with high 
penetrance but which have no 
known direct link to B? 
Figure 2: Principle of Mendelian Randomisation
Identify population with 
alleles causing A
Phenotype for B





















in FH due to 
LDLR mutations
Form of LD  CGL FPLD2 Other FPLD APLD           
Genes AGPAT2, BSLC2 LMNA PPARG, PLIN1 ---
PTRF, CAV1 AKT2, CIDEC 
Fat preserved Sometimes visceral WAT visceral WAT infra-umbilical 
mechanical WAT, head/neck WAT some s/c WAT 
BM WAT labial WAT truncal WAT visceral WAT 
Metabolic Severe IR Severe IR Severe IR Moderate or no IR 
Profile Severe DL Severe DL Severe DL Little DL 
Severe NAFLD Severe NAFLD Severe NAFLD Little or no NAFLD 
Figure 4: Models for Role of Partial Insulin Resistance in Disease Pathogenesis
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